BlackRock’s First Tracks Biotherapeutics TRAX Stock Holding History

BlackRock’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.5M	Buy	+1,963,541	New	+$36.7M	﹤0.01%	2823

Other funds holding TRAX

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

FEG

Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

BlackRock's TRAX Position: Q2 2026 in Review

BlackRock opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 1,963,541 shares worth $39.5M. The stake represents ﹤0.01% of the portfolio and ranks #2823 among its holdings.

38 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

BlackRock held 1,963,541 shares of First Tracks Biotherapeutics worth $39.5M as of Q2 2026.
First Tracks Biotherapeutics was a new BlackRock position in Q2 2026.
First Tracks Biotherapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2823 holding.
38 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.